EMT inhibitor-1

• CAT Number: I019689
• CAS Number: 1638526-21-2
• Molecular Formula: C12H12Cl2N2O2S
• Molecular Weight: 319.21
• Purity: ≥95%
• Synonyms: 4-[[4-(3,4-dichlorophenyl)-1,2,5-thiadiazol-3-yl]oxy]butan-1-ol
• InChI: InChI=1S/C12H12Cl2N2O2S/c13-9-4-3-8(7-10(9)14)11-12(16-19-15-11)18-6-2-1-5-17/h3-4,7,17H,1-2,5-6H2
• InChIKey: FWMUIOJZHOPPDX-UHFFFAOYSA-N
• SMILES: C1=CC(=C(C=C1C2=NSN=C2OCCCCO)Cl)Cl

EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
EMT inhibitor-1 (C19) (0-10μM; 24 hours) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities, inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro[1].
EMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) exerts strong antitumor activity in a mouse tumor model. Mechanistically, EMT inhibitor-1 induces GSK3-β–mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex[1].C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide).

Reference

[1]. Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67.
 [Content Brief]